ClinicalTrials.gg
CompletedNCT04502862MORPHEOUpdated Dec 6, 2024Results posted

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

A Phase 4 interventional study of SAR231893 and Placebo in Asthma, sponsored by Sanofi. Completed at 55 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
13th of 31
202 · median 120
Started
2020
with 3 others
Phase 4
14 of 31
5 open now
Registered
18th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 13th largest by enrollment, is one of 4 that started in 2020, is one of 14 in phase 4, and was the 18th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To assess the effect of dupilumab on sleep

Secondary Objectives:

  • To evaluate the effect of dupilumab on additional participant reported sleep outcomes
  • To evaluate the effect of dupilumab on objective sleep assessment
  • To evaluate the effect of dupilumab on asthma symptoms
  • To evaluate the effect of dupilumab on lung function
  • To evaluate the safety of dupilumab
Read the detailed description

Study duration per participant was approximately 16 weeks and up to 29 weeks including up to 5 weeks screening period, a 12-week treatment period and up to 12 weeks post-treatment follow-up period or until the participant switched to commercialized dupilumab (or other biologic product), whichever came first.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician diagnosis of asthma based on the Global Initiative for Asthma (GINA) 2020 Guidelines for ≥12 months treated with medium to high dose inhaled (ICS) and a second controller (ie, long-acting beta agonist, leukotriene receptor antagonist). A third controller is allowed but not mandatory. The dose regimen should be stable for at least 1 month before the study and during the screening period
  • History of at least one severe asthma exacerbation within 1 year prior to screening. Severe exacerbation is defined as deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic steroids (oral or injectable)
  • Eosinophils ≥150 cells/μL and fractional exhaled nitric oxide (FeNO) ≥25 ppb during screening, prior to randomization

    • NOTES:
    • Historical values of blood eosinophil count meeting the eligibility criterion measured within 6 months prior to screening Visit 1 in the absence of oral corticosteroid (OCS) treatment are allowed
    • FeNO value to be checked for eligibility at Visit 2 as well
  • Asthma control questionnaire (ACQ)-5 ≥2.5 at screening Visit 1 and Visit 2, prior to randomization
  • Pre-bronchodilator (FEV1) ≤ 80% of predicted normal during screening and at Visit 2, prior to randomization
  • Exhibit bronchodilator reversibility (≥12% and 200 mL improvement in FEV1 post short-acting beta agonist administration) during screening period, prior to randomization, unless reversibility test meeting the inclusion criteria was done within 6 months prior to screening Visit 1
  • Weekly average nocturnal awakenings due to asthma symptoms in the week prior to screening Visit 1 is ≥1

Exclusion criteria

Exclusion Criteria:

  • Current smoker
  • Former smoker for 10 years with a smoking history of >10 pack-years
  • Severe asthma exacerbation during screening, prior to randomization
  • History or clinical evidence of (COPD) including Asthma-COPD Overlap Syndrome (ACOS) or any other significant lung disease (eg, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome)
  • History of or current evidence of non-respiratory diseases that in the opinion of the investigator may interfere with the aims of the study or put the participant at undue risk
  • Active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated TB will be excluded unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist. Tuberculosis testing would be performed on a country by country basis, according to local guidelines if required by Regulatory Authorities or ethics boards
  • Diagnosed active endoparasitic infection; suspected or high risk of endoparasitic infection, unless clinical and (if necessary) laboratory assessment have ruled out active infection before randomization
  • History of human immunodeficiency () infection or positive HIV test at screening Visit 1
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before screening
  • Known or suspected immunodeficiency including history of invasive opportunistic infections, despite infection resolution
  • Current evidence of clinically significant oncological disease
  • History of systemic or anaphylaxis to any biologic therapy
  • Severe uncontrolled depression
  • Sleep disturbances not related to asthma, including sleep apnea, hypersomnia, or insomnia secondary to chronic pain, atopic dermatitis (AD), COPD or other conditions
  • Participant who works night shift (ie, any work between 8 pm and 6 am)
  • Erratic sleep habits, as determined by the Investigator
  • Restless leg syndrome or periodic limb movement disorder
  • Chronic treatment with oral (OCS) for more than 2 weeks before screening Visit 1
  • Participant taking sedative, anxiolytic, or hypnotic treatments, including melatonin, within 3 months before randomization
  • Participant taking systemic sedative antihistamines (excluding newer generations of antihistamines) or theophylline
  • Current treatment with antidepressants, lipophilic beta blockers, clonidine, opioids, or other medications known to interfere with sleep and may confound the study assessments, as determined by the Investigator
  • Participant who has taken biologic therapy (including dupilumab)/systemic to treat inflammatory disease or disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc) within 2 months or 5 half-lives before screening Visit 1, whichever is longer
  • Treatment with live (attenuated) vaccine within 4 weeks before screening Visit 1

    • NOTE: For participants who have vaccination with live, attenuated vaccines planned during the course of the study (based on national vaccination schedule/local guidelines), it will be determined, after consultation with a physician, whether the administration of vaccine can be postponed until after the end of the study, (i.e. after the 12 week follow-up period off-treatment or until the participant switches to commercialized dupilumab or other biologic product, whichever comes first), or preponed to before the start of the study without compromising the health of the participant:
    • Participant for whom administration of live (attenuated) vaccine can be safely postponed would be eligible to enroll into the study
    • Participant who have their vaccination preponed can enroll in the study only after a gap of 4 weeks following administration of the vaccine

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Participants received a loading dose of 400 mg of dupilumab (2 injections × 200 mg) SC on Day 1, followed by 200 mg Q2W for 12 weeks.

    Drug: SAR231893

  • Placebo comparator
    Placebo

    Participants received an initial loading dose of matching placebo (2 injections of placebo) SC on Day 1, followed by 1 injection of placebo Q2W for 12 weeks.

    Drug: Placebo

Interventions

  • Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

    Also known as: Dupixent

  • DrugPlacebo

    Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)

    The ASDQ is a participant-reported outcome (PRO) measure designed to assess the impact of asthma on participants' sleep. Participants were instructed to record the severity of the disturbance of their sleep due to asthma as: 0 = slept through the night, no asthma symptoms; 1 = slept well, no night time awakenings because of asthma, but some asthma symptoms in the morning; 2 = woke up once because of asthma (may or may not include early awakening); 3 = woke up several times because of asthma (may or may not include early awakening) and 4 = bad night, awake most of the night because of asthma. The participants recorded their sleep disturbance in an electronic diary, once a day upon awakening. Total scores ranges between 0 to 4 with 0 indicating no impact of asthma on sleep and 4 indicating higher impact of asthma on sleep. Higher scores indicated worse outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (Day -6 to Day 1) up to Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 on the Number of Nocturnal Awakenings (Sleep Diary)

    Sleep diary is used to assess adult sleep disturbance due to asthma. Number of nocturnal awakenings was determined based on answer on question from sleep diary: "Approximately how many times did you wake up last night (not including when you woke up for the day today)?" Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (Day -6 to Day 1) up to Week 12

  2. Change From Baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a Scale

    PROMIS sleep-related impairment eight-term 8a scale was administered to assess impact of sleep-related impairment during waking hours. The questionnaire focuses on self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. It assesses sleep-related impairment over the past 7 days. Each item is rated on a 5-point scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) with a raw score from 8 to 40 with higher scores indicating greater sleep impairment. PROMIS T-score is presented which rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. Possible range for T-score=30 to 80; higher scores=greater severity of sleep impairment. Baseline=last available valid (non-missing) value up to and including the day of first dose of investigational medicinal product (IMP).

    Time frame: Baseline (Day 1) up to Week 12

  3. Change From Baseline to Week 12 in Sleep Quality (Sleep Diary)

    Sleep diary is used to assess adult sleep disturbance due to asthma. Sleep quality was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (Day -6 to Day 1) up to Week 12

  4. Change From Baseline to Week 12 in Restorative Sleep (Sleep Diary)

    Sleep Diary is used to assess adult sleep disturbance due to asthma. Question about restorative sleep asks participants to recall "when they got up for the day today". Restorative sleep was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (Day -6 to Day 1) up to Week 12

  5. Change From Baseline to Week 12 in Wake After Sleep Onset (WASO) (Sleep Diary)

    Sleep Diary is used to assess adult sleep disturbance due to asthma. WASO was calculated as time awake after initial sleep onset but before the final awakening. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (Day -6 to Day 1) up to Week 12

  6. Change From Baseline to Week 12 in WASO Based on Actigraphy Data

    Wrist actigraphy is a procedure that records and integrates occurrence and degree of limb movement activity over an extended recording period. The signals generated by wrist movement are sensed by a tiny microcomputer contained within watch and translated into activity counts. Algorithms have been developed to translate these activity counts or "epochs" (or "periods") that correspond to times when a person is likely to be asleep or wake. Actigraph was worn on wrist of non-dominant hand to provide estimates of duration, timing and patterns of sleep in study participants. After the watch data were scored by a selected expert center, a number of summary measurements were generated for each participant, including WASO. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (Day -6 to Day 1) up to Week 12

  7. Change From Baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD)

    The ADSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ADSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ADSD every night before they go to bed, thinking about their asthma symptoms today, from when they got up this morning until now. ADSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -7 to Day -1.

    Time frame: Baseline (Day -7 to Day -1) up to Week 12

  8. Change From Baseline to Week 12 in Asthma Nighttime Symptom Diary (ANSD)

    The ANSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ANSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ANSD when getting up, thinking about their asthma symptoms last night from when they went to bed until now. ANSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -6 to Day -1.

    Time frame: Baseline (Day -6 to Day -1) up to Week 12

  9. Change From Baseline to Week 12 in Pre-Bronchodilator Forced Expiratory Volume (Pre-BD FEV1)

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. For pre-BD FEV1, spirometry was performed before IMP administration and after withholding the standard of care asthma treatment which was verified before performing the measurements. Baseline was defined as the last available valid (non-missing) value up to and including the day of first dose of IMP.

    Time frame: Baseline (Day 1) up to Week 12

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-Emergent Adverse Events Of Special Interest (TEAESIs)

    AE: any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs: AEs that developed or worsened or became serious during TEAE period, defined as time from first administration of IMP (on Day 1) to last administration of IMP + 98 days or until participant switches to commercialized dupilumab or other biologics. SAE: any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. AESI: AE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor is required.

    Time frame: From first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks

  11. Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs

    Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and weight. Criteria for PCSA: SBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg, ≥160 mmHg and increase from baseline ≥20 mmHg; DBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; HR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% increase from baseline, ≥5% decrease from baseline.

    Time frame: From first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks

07

Results

Posted Nov 26, 2024

Participant flow

The study was conducted at 52 centers in 11 countries. A total of 397 participants were screened between 10 August 2020 to 30 May 2023, of which 195 participants were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

Participant flow — Overall Study
MilestoneDupilumab 200 mg Q2WPlacebo
Started101101
Randomized and treated100101
Completed9594
Not completed67
Withdrew: Not related to coronavirus disease-2019 (covid-19) pandemic46
Withdrew: Withdrawal by subject10
Withdrew: Adverse event11

Outcome measures

PrimaryChange From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)

The ASDQ is a participant-reported outcome (PRO) measure designed to assess the impact of asthma on participants' sleep. Participants were instructed to record the severity of the disturbance of their sleep due to asthma as: 0 = slept through the night, no asthma symptoms; 1 = slept well, no night time awakenings because of asthma, but some asthma symptoms in the morning; 2 = woke up once because of asthma (may or may not include early awakening); 3 = woke up several times because of asthma (may or may not include early awakening) and 4 = bad night, awake most of the night because of asthma. The participants recorded their sleep disturbance in an electronic diary, once a day upon awakening. Total scores ranges between 0 to 4 with 0 indicating no impact of asthma on sleep and 4 indicating higher impact of asthma on sleep. Higher scores indicated worse outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (Day -6 to Day 1) up to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)
Score on a scaleDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)-0.88 ± 0.077-0.81 ± 0.077
Statistical analysis
  • Dupilumab 200 mg Q2W vs Placebo · MMRM · p = 0.512 (A hierarchical testing procedure was used to control type I error and handle primary and first 2 secondary endpoints (reported sequentially) analyses at a 2-sided significance level of 0.05.) · Least square mean difference: -0.07 · 95% CI -0.28 to 0.14
SecondaryChange From Baseline to Week 12 on the Number of Nocturnal Awakenings (Sleep Diary)

Sleep diary is used to assess adult sleep disturbance due to asthma. Number of nocturnal awakenings was determined based on answer on question from sleep diary: "Approximately how many times did you wake up last night (not including when you woke up for the day today)?" Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (Day -6 to Day 1) up to Week 12
Reported as:
Least squares mean · Number of nocturnal awakenings
Change From Baseline to Week 12 on the Number of Nocturnal Awakenings (Sleep Diary)
Number of nocturnal awakeningsDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 on the Number of Nocturnal Awakenings (Sleep Diary)-0.71 ± 0.080-0.71 ± 0.080
Statistical analysis
  • Dupilumab 200 mg Q2W vs Placebo · MMRM · p = 0.967 (A hierarchical testing procedure was used to control type I error and handle primary and first 2 secondary endpoints (reported sequentially) analyses at a 2-sided significance level of 0.05.) · Least square mean difference: 0.00 · 95% CI -0.21 to 0.22
SecondaryChange From Baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a Scale

PROMIS sleep-related impairment eight-term 8a scale was administered to assess impact of sleep-related impairment during waking hours. The questionnaire focuses on self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. It assesses sleep-related impairment over the past 7 days. Each item is rated on a 5-point scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) with a raw score from 8 to 40 with higher scores indicating greater sleep impairment. PROMIS T-score is presented which rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. Possible range for T-score=30 to 80; higher scores=greater severity of sleep impairment. Baseline=last available valid (non-missing) value up to and including the day of first dose of investigational medicinal product (IMP).

Time frame:
Baseline (Day 1) up to Week 12
Reported as:
Least squares mean · T-score
Change From Baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a Scale
T-scoreDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a Scale-7.20 ± 0.624-6.51 ± 0.626
Statistical analysis
  • Dupilumab 200 mg Q2W vs Placebo · MMRM · p = 0.422 (A hierarchical testing procedure was used to control type I error and handle primary and first 2 secondary endpoints (reported sequentially) analyses at a 2-sided significance level of 0.05) · Least square mean difference: -0.70 · 95% CI -2.40 to 1.01
SecondaryChange From Baseline to Week 12 in Sleep Quality (Sleep Diary)

Sleep diary is used to assess adult sleep disturbance due to asthma. Sleep quality was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (Day -6 to Day 1) up to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Week 12 in Sleep Quality (Sleep Diary)
Score on a scaleDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Sleep Quality (Sleep Diary)1.14 ± 0.1510.97 ± 0.152
SecondaryChange From Baseline to Week 12 in Restorative Sleep (Sleep Diary)

Sleep Diary is used to assess adult sleep disturbance due to asthma. Question about restorative sleep asks participants to recall "when they got up for the day today". Restorative sleep was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (Day -6 to Day 1) up to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Week 12 in Restorative Sleep (Sleep Diary)
Score on a scaleDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Restorative Sleep (Sleep Diary)1.15 ± 0.1521.02 ± 0.152
SecondaryChange From Baseline to Week 12 in Wake After Sleep Onset (WASO) (Sleep Diary)

Sleep Diary is used to assess adult sleep disturbance due to asthma. WASO was calculated as time awake after initial sleep onset but before the final awakening. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (Day -6 to Day 1) up to Week 12
Reported as:
Least squares mean · Minutes
Change From Baseline to Week 12 in Wake After Sleep Onset (WASO) (Sleep Diary)
MinutesDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Wake After Sleep Onset (WASO) (Sleep Diary)-30.58 ± 3.945-26.48 ± 3.962
SecondaryChange From Baseline to Week 12 in WASO Based on Actigraphy Data

Wrist actigraphy is a procedure that records and integrates occurrence and degree of limb movement activity over an extended recording period. The signals generated by wrist movement are sensed by a tiny microcomputer contained within watch and translated into activity counts. Algorithms have been developed to translate these activity counts or "epochs" (or "periods") that correspond to times when a person is likely to be asleep or wake. Actigraph was worn on wrist of non-dominant hand to provide estimates of duration, timing and patterns of sleep in study participants. After the watch data were scored by a selected expert center, a number of summary measurements were generated for each participant, including WASO. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (Day -6 to Day 1) up to Week 12
Reported as:
Least squares mean · Minutes
Change From Baseline to Week 12 in WASO Based on Actigraphy Data
MinutesDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in WASO Based on Actigraphy Data-1.64 ± 2.286-1.17 ± 2.215
SecondaryChange From Baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD)

The ADSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ADSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ADSD every night before they go to bed, thinking about their asthma symptoms today, from when they got up this morning until now. ADSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -7 to Day -1.

Time frame:
Baseline (Day -7 to Day -1) up to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD)
Score on a scaleDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD)-1.78 ± 0.192-1.56 ± 0.193
SecondaryChange From Baseline to Week 12 in Asthma Nighttime Symptom Diary (ANSD)

The ANSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ANSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ANSD when getting up, thinking about their asthma symptoms last night from when they went to bed until now. ANSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -6 to Day -1.

Time frame:
Baseline (Day -6 to Day -1) up to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Week 12 in Asthma Nighttime Symptom Diary (ANSD)
Score on a scaleDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Asthma Nighttime Symptom Diary (ANSD)-1.58 ± 0.178-1.36 ± 0.178
SecondaryChange From Baseline to Week 12 in Pre-Bronchodilator Forced Expiratory Volume (Pre-BD FEV1)

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. For pre-BD FEV1, spirometry was performed before IMP administration and after withholding the standard of care asthma treatment which was verified before performing the measurements. Baseline was defined as the last available valid (non-missing) value up to and including the day of first dose of IMP.

Time frame:
Baseline (Day 1) up to Week 12
Reported as:
Least squares mean · Liter
Change From Baseline to Week 12 in Pre-Bronchodilator Forced Expiratory Volume (Pre-BD FEV1)
LiterDupilumab 200 mg Q2WPlacebo
Change From Baseline to Week 12 in Pre-Bronchodilator Forced Expiratory Volume (Pre-BD FEV1)0.49 ± 0.0440.27 ± 0.047
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-Emergent Adverse Events Of Special Interest (TEAESIs)

AE: any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs: AEs that developed or worsened or became serious during TEAE period, defined as time from first administration of IMP (on Day 1) to last administration of IMP + 98 days or until participant switches to commercialized dupilumab or other biologics. SAE: any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. AESI: AE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor is required.

Time frame:
From first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-Emergent Adverse Events Of Special Interest (TEAESIs)
ParticipantsDupilumab 200 mg Q2WPlacebo
Any TEAE4846
Any TESAE33
Any TEAESI00
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs

Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and weight. Criteria for PCSA: SBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg, ≥160 mmHg and increase from baseline ≥20 mmHg; DBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; HR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% increase from baseline, ≥5% decrease from baseline.

Time frame:
From first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs
ParticipantsDupilumab 200 mg Q2WPlacebo
SBP: ≤95 mmHg and decrease from baseline ≥20 mmHg01
SBP: ≥160 mmHg and increase from baseline ≥20 mmHg12
DBP: ≤45 mmHg and decrease from baseline ≥10 mmHg00
DBP: ≥ 110 mmHg and increase from baseline ≥ 10mmHg00
HR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm00
HR: ≥ 120 bpm and increase from baseline ≥ 20 bpm00
Weight: ≥5% increase from baseline36
Weight: ≥5% decrease from baseline54

Adverse events

Collected over TEAEs were collected from first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) up to end of study, approximately 39 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab 200 mg Q2W0/100 (0%)3/100 (3%)13/100 (13%)
Placebo0/101 (0%)3/101 (3%)18/101 (17.8%)
Most frequent serious events
Most frequent serious events
EventDupilumab 200 mg Q2WPlacebo
FallInjury, poisoning and procedural complications1/1000/101
Tibia FractureInjury, poisoning and procedural complications1/1000/101
Depression SuicidalPsychiatric disorders1/1000/101
Suicide AttemptPsychiatric disorders1/1000/101
AsthmaRespiratory, thoracic and mediastinal disorders1/1000/101
Pancreatitis AcuteGastrointestinal disorders0/1001/101
Covid-19 PneumoniaInfections and infestations0/1001/101
UrosepsisInfections and infestations0/1001/101
NephrolithiasisRenal and urinary disorders0/1001/101
Most frequent other events
Most frequent other events
EventDupilumab 200 mg Q2WPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders9/10014/101
NasopharyngitisInfections and infestations4/1007/101

Baseline characteristics

The Intent-to-treat (ITT) analysis set consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)Dupilumab 200 mg Q2WPlaceboTotal
Mean46.9 ± 12.6346.6 ± 12.7146.7 ± 12.64
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab 200 mg Q2WPlaceboTotal
Female6876144
Male332558
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab 200 mg Q2WPlaceboTotal
American Indian or Alaska Native000
Asian437
Native Hawaiian or Other Pacific Islander011
Black or African American448
White9292184
More than one race101
Unknown or Not Reported011
Sleep Disturbance Score
Sleep Disturbance Score(Score on a scale)Dupilumab 200 mg Q2WPlaceboTotal
Mean1.89 ± 0.7691.83 ± 0.7541.86 ± 0.760
08

Study locations

55 sites
  • Kern Allergy and Medical Research. Inc. Site Number : 8400003
    Bakersfield, California 93301, United States
  • Todd Astor MD Site Number : 8400016
    Culver City, California 90230, United States
  • Southern California Institute for Respiratory Diseases Site Number : 8400009
    Los Angeles, California 90048, United States
  • Allergy & Asthma Associates of Santa Clara Valley Site Number : 8400001
    San Jose, California 95117, United States
  • Asthma and Allergy Associates, PC Site Number : 8400011
    Colorado Springs, Colorado 80907, United States
  • Sarasota Clinical Research Site Number : 8400012
    Sarasota, Florida 34239, United States
  • Allergy & Asthma Specialists, PSC Site Number : 8400004
    Owensboro, Kentucky 42301, United States
  • The Asthma and Allergy Center Site Number : 8400010
    Bellevue, Nebraska 68123, United States
  • OK Clinical Research LLC Site Number : 8400005
    Edmond, Oklahoma 73034, United States
  • Velocity Clinical Research, Medford Site Number : 8400007
    Medford, Oregon 97504, United States
  • National Allergy and Asthma Research, LLC Site Number : 8400008
    Charleston, South Carolina 29407, United States
  • TTS Research Site Number : 8400006
    Boerne, Texas 78006, United States
  • Investigational Site Number : 0320003
    Caba, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number : 0320001
    Caba, Buenos Aires C1425FVH, Argentina
  • Investigational Site Number : 0320004
    Rosario, Santa Fe S2000DEJ, Argentina
  • Investigational Site Number : 0320005
    Rosario, Santa Fe S2002OJP, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number : 1240012
    Ajax, Ontario L1S 2J5, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M9V 4B4, Canada
  • Investigational Site Number : 1240009
    Quebec, G1G 3Y8, Canada
  • Investigational Site Number : 1240008
    Windsor, N8X 5A6, Canada
  • Investigational Site Number : 2760002
    Berlin, 10787, Germany
  • Investigational Site Number : 2760005
    Frankfurt am Main, 60596, Germany
  • Investigational Site Number : 2760003
    Hannover, 30173, Germany
  • Investigational Site Number : 2760001
    Koblenz, 56068, Germany
  • Investigational Site Number : 2760004
    Leipzig, 04347, Germany
  • Investigational Site Number : 2760006
    Lübeck, 23552, Germany
  • Investigational Site Number : 3800006
    Monserrato, Cagliari 09042, Italy
  • Investigational Site Number : 3800001
    Orbassano, Torino 10043, Italy
  • Investigational Site Number : 3800005
    Reggio Emilia, 42123, Italy
  • Investigational Site Number : 5280005
    Arnhem, 6815 AD, Netherlands
  • Investigational Site Number : 5280001
    Breda, 4818 CK, Netherlands
  • Investigational Site Number : 5280002
    Leeuwarden, 8934 AD, Netherlands
  • Investigational Site Number : 6200001
    Aveiro, 3810-501, Portugal
  • Investigational Site Number : 6200007
    Guimarães, 4810-061, Portugal
  • Investigational Site Number : 6200006
    Lisboa, 1769, Portugal
  • Investigational Site Number : 6200003
    Matosinhos, 4464-513, Portugal
  • Investigational Site Number : 6200004
    Porto, 4202-451, Portugal
  • Investigational Site Number : 6430001
    Moscow, 115093, Russian Federation
  • Investigational Site Number : 6430002
    Moscow, 115280, Russian Federation
  • Investigational Site Number : 6430006
    Moscow, 115478, Russian Federation
  • Investigational Site Number : 6430005
    Moscow, 117546, Russian Federation
  • Investigational Site Number : 6430007
    St-Petersburg, 193231, Russian Federation
  • Investigational Site Number : 6430004
    St-Petersburg, 194354, Russian Federation
  • Investigational Site Number : 7240001
    Lugo / Lugo, Galicia [Galicia] 27003, Spain
  • Investigational Site Number : 7240002
    Valencia, Valenciana, Comunidad 46017, Spain
  • Investigational Site Number : 7240005
    Madrid, 28006, Spain
  • Investigational Site Number : 8040002
    Ivano-Frankivsk, 76018, Ukraine
  • Investigational Site Number : 8040006
    Ivano-Frankivsk, 76018, Ukraine
  • Investigational Site Number : 8040003
    Kharkiv, 61166, Ukraine
  • Investigational Site Number : 8040008
    Kyiv, 01023, Ukraine
  • Investigational Site Number : 8040007
    Kyiv, 01033, Ukraine
  • Investigational Site Number : 8040005
    Vinnytsya, 21001, Ukraine
  • Investigational Site Number : 8260001
    Cambridge, Cambridgeshire CB2 2QQ, United Kingdom
  • Investigational Site Number : 8260002
    London, London, City Of EC1M 6BQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2023, 37 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 37 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 6, 2020
StartActual
Aug 10, 2020
Primary completionActual
Oct 3, 2023
CompletionActual
Nov 10, 2023
Results first posted
Nov 26, 2024
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04502862
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 6, 2020
Start date
Aug 10, 2020
Primary completion
Oct 3, 2023
Completion
Nov 10, 2023
Results posted
Nov 26, 2024
Last update
Dec 6, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion